$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
靶向药索托拉西布(Sotorasib)的中文说明书
2025-10-19 11:44:20
Check Details
索托拉西布(Sotorasib)的用法用量:用药指南,剂量调整,特殊人群用药,用药注意事项
2025-10-19 11:44:20
Check Details
靶向药康奈非尼(Braftovi)Braftovi,恩考芬尼的详细说明书
2025-10-19 11:44:20
Check Details
原发性乳腺癌的炎症特征
2025-10-19 11:44:20
Check Details
乳腺癌药物帕博西林(哌柏西利)的作用机制
2025-10-19 11:44:20
Check Details
哌柏西利,晚期乳腺癌患者的新希望
2025-10-19 11:44:20
Check Details
三阴乳腺癌危害的主要表现
2025-10-19 11:44:20
Check Details
乳腺癌高危因素
2025-10-19 11:44:20
Check Details
加强筛查是提高乳腺癌生存率的关键
2025-10-19 11:44:20
Check Details
依维莫司(飞尼妥)是首个用于乳腺癌的mTOR抑制剂
2025-10-19 11:44:20
Check Details
乳腺癌术后护理注意事项
2025-10-19 11:44:20
Check Details
乳腺癌典型症状表现
2025-10-19 11:44:20
Check Details
1
2
...
1645
1646
1647
1648
1649
1650
1651
...
4158
4159
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
2
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights
3
Pemigatinib vs. Anlotinib: Key Differences Between FGFR-Targeted Therapy and Multi-Target Anti-Angiogenic Treatment
4
Lapatinib: A Targeted Anticancer Agent — Not Merely Symptom Relief
5
Lapatinib: Proper Administration Guide and Key Precautions
6
Capivasertib (Truqap) Complete Medication Guide: Indications, Dosing, Safety, and Precautions
7
Cemiplimab Storage and Handling Guide
8
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Dosing Duration, Efficacy Comparison, and Long-Term Management
9
Belzutifan (Welireg): Comprehensive Guide to the First HIF-2α Inhibitor — Indications, Dosing, and Safety Monitoring
10
Encorafenib (Braftovi): Comprehensive Guide to BRAF V600 Inhibitor Indications, Dose Regimens by Tumor Type, and Administration Requirements
11
Alpelisib vs Inavolisib: How to Choose Between Two PI3Kα Inhibitors in PIK3CA-Mutated Breast Cancer
12
Selumetinib: The First MEK1/2 Inhibitor Approved for Inoperable Plexiform Neurofibromas in NF1